Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2

Open access
Wu, Leyun, Zhou, Liping, Mo, Mengxia, Liu, Tingting, Wu, Chengkun, Gong, Chunye, Lu, Kai, Gong, Likun, Zhu, Weiliang, Xu, Zhijian · 2022 · Signal Transduction and Targeted Therapy

Abstract

SARS-coronavirus-2 (SARS-CoV-2) Omicron variant (B.1.1.529) is of great concern to the world due to its multiple mutations that may have an impact on transmissibility and immune evasion. 1 Compared to the wild type (WT), Omicron carries as many as 30 single point mutations, 3 deletion mutation and one insertion mutation on its spike protein. Strikingly, there are 15 mutations observed in the Omicron receptor-binding domain (RBD), 10 of which are in the receptor-binding motif (RBM) that human angiotensin-converting enzyme 2 (ACE2) and most monoclonal antibodies (mAbs) interact directly with. As a comparison, the currently dominant variant Delta (B.1.617.2) has only 2 mutations (L452R and T478K) in its RBM and additional K417N and E484K mutations sometimes. Therefore, Omicron variant may significantly impact the binding affinity to ACE2 and effectiveness of currently available mAbs. Consequently, Omicron mutant has aroused wide concern, many countries have taken measures on entry restrictions to prevent its rapid spread. However, the transmissibility and immune evasion risk of Omicron have not been properly evaluated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00863-2

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 210

Metadata

Authors
Wu, L., Zhou, L., Mo, M., Liu, T., Wu, C., Gong, C., Lu, K., Gong, L., Zhu, W., & Xu, Z.
Venue
Signal Transduction and Targeted Therapy
Published
2022-01-05
Volume
7
Issue
1
Pages
8-8
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4206655041
Cited by
210
References
2
FWCI
22.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. https://app.cochat.ai/papers/10.1038/s41392-021-00863-2
The paper
Wu, L., Zhou, L., Mo, M., Liu, T., Wu, C., Gong, C., Lu, K., Gong, L., Zhu, W., & Xu, Z. (2022). SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00863-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.